This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. Patients with AF had a higher annual incidence of stroke/transient ischaemic attack (2.6 Methods Overall, 1739 adult patients with HCM (40.9% vs 1.7%, p=0.053).
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
This review provides information about the current evidence-base for screening for atrialfibrillation (AF). Finally, novel methods to refine the population to whom AF screening should be offered, which may improve clinical and cost-effectiveness, are considered.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.
Atrialfibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heart failure, dementia and stroke. It constitutes a significant burden to healthcare systems, making its early detection and treatment a major goal.
BackgroundAn increased risk of recurrent stroke is noted in patients with atrialfibrillation despite direct oral anticoagulant (DOAC) use. A total of 84 patients experienced recurrent ischemic stroke after switching to different oral anticoagulants, with a total follow‐up time of 14 years. 0.41] for rivaroxaban).ConclusionsIn
Background Efforts to maintain sinus rhythm in patients with persistent atrialfibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. At 36 months, all patients were alive with no new stroke/transient ischaemic attack (TIA). All were longstanding persistent.
Stroke recovery is a challenging process that extends for months after hospital discharge. To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. After the stroke, I had new prescriptions, and this was the first obstacle for me.
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
Atrialfibrillation is the most common sustained arrhythmia. Females with atrialfibrillation have been known to have an increased risk of stroke. However, racial disparities in outcomes in atrialfibrillation patients have been less studied.
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrialfibrillation. ResultsA total of 12 studies included 73,824 patients with atrialfibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrialfibrillation (AFib) who are at an increased risk of stroke. A statistically significant lower number of fatal or disabling strokes with Amulet (22 vs. 39). 16-18, 2024).
Introduction Atrialfibrillation (AF) is associated with a fivefold increased risk of stroke. Oral anticoagulation reduces the risk of stroke, but AF is elusive.
BackgroundThe impact of atrialfibrillation (AF) on the clinical outcomes in patients with acute ischemic stroke (AIS) who received endovascular thrombectomy remains unclear. Data were meta‐analyzed to compare the outcomes among patients with AIS with and without AF who received endovascular thrombectomy.
BackgroundAs the population ages, atrialfibrillation (AF) prevalence increases, but data on optimal oral anticoagulation (OAC) in patients 80 years remain limited. Data were analyzed by age for outcomes and risk factors for predefined end points.ResultsPatients 80 years comprised 32.2% of AF cases. of AF cases. versus 70.5%,P=0.0070).
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrialfibrillation (PAF) remains controversial.
Background Atrialfibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of stroke. Finally, four indicators were included, namely, previous stroke/transient ischaemic attack (OR = 4.25, 95% CI = 1.57–12.23, 12.23, P = 0.006), left atrial volume index (LAVI) (OR = 1.04, 95% CI = 1.01–1.06,
Objective Implantable loop recorders (ILRs) are increasingly used for long-term rhythm monitoring after ischaemic and cryptogenic stroke, with the goal of detecting atrialfibrillation (AF) and subsequent initiation of oral anticoagulation to reduce risk of adverse clinical outcomes. Mean age was 69.9 (SD years and 53.5%
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
Atrialfibrillation (AF) is a common arrhythmia in patients with heart failure (HF). The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1].
Background Evaluating outcomes of concurrent Cox-Maze procedures in elderly patients undergoing high-risk cardiac surgery. Mehods We retrospectively identified patients aged over 70 years with AtrialFibrillation (AF) from 2011 to 2017 who had two or more other cardiac procedures. They were subdivided into two groups: 1.
Background:While anticoagulation is crucial for atrialfibrillation (AF) patients to prevent ischemic events, those with thrombocytopenia have a potential increased risk of bleeding. The primary outcome was all-cause inpatient mortality. There was no significant difference in ischemic stroke risk (aOR 0.67, 95% CI 0.37-1.21,
Atrialfibrillation often shortened to AFib is an irregular and often rapid heart rhythm that can lead to serious health complications. In some cases, AFib can also increase the risk of stroke, blood clots and heart failure. The post How to Prevent an AtrialFibrillation Attack appeared first on AMS Cardiology.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP87-ATMP87, February 1, 2024. Background and purpose:Because the biochemical composition of thrombus changes after formation over time, thrombus maturation in the left atrium may affect clot compositions in ischemic stroke with atrialfibrillation (AF).
BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrialfibrillation (AF), data on patients with AF and valvular heart disease remain scarce. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety.
The introduction of Bruton Tyrosine Kinase inhibitors (BTKi) to the Chronic Lymphocytic Leukemia (CLL) treatment armamentarium has facilitated a significant improvement in overall outcomes. Incident atrialfibrillation (AF) has been identified as the most common reason for discontinuation of BTKi, limiting therapeutic utility of these agents.
These findings suggest opportunities to enhance clinical practice and improve outcomes for Medicare patients undergoing esophagectomy for cancer. They note a substantial increase in the frequency of these surgeries, emphasizing the importance of understanding outcomes.
Stroke: Vascular and Interventional Neurology, Volume 4, Issue 6 , November 1, 2024. Data on patients with acute ischemic stroke from the Third China National Stroke Registry were analyzed. Patients with preexisting heart diseases had higherprevalence of moderate or severe stroke at admission (4.7%
Stroke, Volume 55, Issue Suppl_1 , Page ATP269-ATP269, February 1, 2024. The association between AF and IS outcomes differed by IS therapy (Table 1). AF patients had an increased odds of a worse mRS (Ordinal OR 2.05, 95% CI 1.14-3.71), 3.71), but not after adjustment (Ordinal OR 1.07, 95% CI 0.52-2.20). respectively).
ABSTRACT Background Anemia is frequently observed as a comorbidity in atrialfibrillation (AF), especially in elderly patients and in those on anticoagulation. This has been associated with poor clinical outcomes. We aim to investigate the impact of anemia on clinical outcomes in patients with AF on oral anticoagulation.
Atrialfibrillation (AF) is the most common arrhythmia in the U.S., Black Americans are less prone to develop AF than White Americans, but they display a higher burden of modifiable risk factors for cardiovascular disease and higher rates of ischemic stroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWP87-AWP87, February 1, 2025. Introduction:Continuous electrocardiographic monitoring using an implantable loop recorder (ILR) can facilitate the detection of asymptomatic atrialfibrillation episodes. The median time from implantation to the first detected atrialfibrillation was 115.7
Stroke, Volume 55, Issue Suppl_1 , Page ATP230-ATP230, February 1, 2024. Introduction:Atrial fibrillation (AF) and cancer are both independently associated with worse outcomes in patients with acute ischemic stroke. Few studies have evaluated the impact of AF on outcomes of cancer-related stroke.
ABSTRACT Background The epidemiological landscape and treatment efficacy of atrialfibrillation (AF) in the Middle East, notably in the United Arab Emirates (UAE), remain under-explored, presenting a distinct demographic and clinical pattern compared to Western populations. No strokes were reported during the study period.
Limited data indicate an elevated risk of atrialfibrillation (AF) after neoadjuvant chemoradiation in esophageal cancer however the role of AF as an independent predictor of outcomes post-esophagectomy remains under-studied. Outcomes over a 5-year period were mortality, ischemic stroke, and use of anticoagulation.
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrialfibrillation (AFib). Additional Resources: After Nov.
Recent studies have demonstrated that early rhythm control for first-line treatment of atrialfibrillation (AF) improved cardiovascular outcomes. However, there is limited data regarding the long-term outcome of patients who failed antiarrhythmic drugs and who refuse radiofrequency catheter ablation (RFCA).
Background Amiodarone is an established treatment for atrialfibrillation (AF) but might interfere with the metabolism of apixaban or warfarin. The primary outcome was major bleeding resulting in hospitalisation based on International Classification of Diseases (ICD)-10 codes. 100 patient-years) and warfarin cohort (4.5/100
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8
BackgroundAlthough older patients with atrialfibrillation are at heightened risk of thromboembolic and bleeding events, their optimal treatment choice remains uncertain.Methods and ResultsThis meta‐analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. prospero/.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content